

| | | | |
|--------------------------------------|--|---------------------------------|-------------|
| Principal Investigator: | Tara Sanft, MD | HIC #: | 1607018037 |
| Funding Source: | Alliance for Clinical Trials in Oncology | Sponsor Protocol Number: | A011401 |
| Sponsor ICF Template Version: | Protocol Version Date 31-Aug-2016 | Protocol Version: | Update #1 |
| Sponsor ICF Template Date: | Protocol Version Date 31-Aug-2016 | Protocol Date: | 31-Aug-2016 |

**COMPOUND AUTHORIZATION AND CONSENT FOR PARTICIPATION IN A
RESEARCH PROJECT
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN
HOSPITAL/SMILOW CANCER HOSPITAL CARE CENTERS/SAINT FRANCIS
HOSPITAL**

Study Title: Breast Cancer WEight Loss Study (BWEL Study) - Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Principal Investigator: Tara Sanft, MD

Principal Investigator's Phone Number: (203) 785-2876

24-Hour Phone Number: (203) 785-4191

Principal Investigator's Mailing Address: 300 George St, Suite 120, New Haven, CT 06511

This study is conducted by the Alliance for Clinical Trials in Oncology, a national clinical research group supported by the National Cancer Institute. The Alliance is made up of cancer doctors, health professionals, and laboratory researchers, whose goal is to develop better treatments for cancer, to prevent cancer, to reduce side effects from cancer, and to improve the quality of life of cancer patients.

What is the usual approach to my breast cancer?

Breast cancer is usually treated with surgery, chemotherapy, radiation and/or medications that lower or block the hormone estrogen. Although many doctors may recommend that obese and overweight patients lose weight, eat a healthy diet and get regular exercise after being diagnosed with breast cancer, these things are not a routine part of breast cancer treatment at this time.

What are my other choices if I do not take part in this study?

If you decide not to take part in this study, you have other choices. For example:

- you may choose to have the usual approach to your cancer described above
- you may choose to take part in a different study, if one is available
- you may take part in a weight loss program on your own, outside of this study

Why is this study being done?

This study is being done to see if losing weight may help prevent breast cancer from coming back (recurring). Previous studies have found that women who are overweight or obese when their breast cancer is found (diagnosed) have a greater risk of their breast cancer recurring, as compared to women who were thinner when their cancer was diagnosed. At this time we do not know whether or not losing weight will reduce the risk of breast cancer returning. This study seeks to determine whether or not the higher risk for breast cancer recurrence in women who are overweight or obese when they are diagnosed with breast cancer could be reduced or eliminated if weight is lost. It is important to note that we do not know how much weight would need to be lost to lower the risk of breast cancer recurrence, or whether this strategy would work for all

| | | | |
|--------------------------------------|--|---------------------------------|-------------|
| Principal Investigator: | Tara Sanft, MD | HIC #: | 1607018037 |
| Funding Source: | Alliance for Clinical Trials in Oncology | Sponsor Protocol Number: | A011401 |
| Sponsor ICF Template Version: | Protocol Version Date 31-Aug-2016 | Protocol Version: | Update #1 |
| Sponsor ICF Template Date: | Protocol Version Date 31-Aug-2016 | Protocol Date: | 31-Aug-2016 |

women. This study will help to show us whether weight loss programs should be a part of breast cancer treatment.

There will be about 3136 women taking part in this study.

What are the study groups?


This study has two study groups.

- Group 1 will get a Health Education program that is designed to give women more information about their breast cancer, as well as general information about their general health. Women who are assigned to this group will receive a subscription to a Health magazine and they will receive mailings twice per year with brochures that provide information about breast cancer and health issues. Women will also receive a study newsletter twice per year, and will be able to take part in webinars or teleconferences twice per year that provide information about new updates in breast cancer. Finally, they will get greeting cards on the anniversary of joining the study, holidays, etc.
- Group 2 will get the Health Education program described above and will also get a 2-year weight loss program. This program will be designed to help women lose about 10% of their starting weight by decreasing the calories they eat and by increasing their exercise. Exercise goals will increase slowly over the study, with an overall goal of getting all women exercising at least 150 minutes per week over time. The weight loss program will be provided through a series of 42 telephone calls over 2 years. Each call will take 20-30 minutes. Each woman will be assigned a health coach who will work with her over the 2-year program. Women will need to track the food they eat and the exercise they do each day, especially in the early stages of the program. This will take approximately 15-20 minutes per day. Coaches will track progress using computer programs to help set goals over the 2-year program. Telephone calls will occur more often at the start of the study and become less frequent over time. Women in the weight loss group will also receive:
 - A weight loss workbook (available in print and on line)
 - An activity sensor (such as a FitBit) to help keep track of exercise
 - A cookbook
 - A journal and access to a study website to track diet, weight and exercise
 - A scale, food scale and measuring cups (if needed)
 - Optional text messages to help women meet exercise and diet goals
 - Optional pre-packaged shakes, bars or portion-controlled entrees to replace meals

A computer will by chance assign you to one of study groups described above. This is called randomization. This is done by chance because no one knows if one study group is better or worse than the others.

| | | | |
|--------------------------------------|--|---------------------------------|-------------|
| Principal Investigator: | Tara Sanft, MD | HIC #: | 1607018037 |
| Funding Source: | Alliance for Clinical Trials in Oncology | Sponsor Protocol Number: | A011401 |
| Sponsor ICF Template Version: | Protocol Version Date 31-Aug-2016 | Protocol Version: | Update #1 |
| Sponsor ICF Template Date: | Protocol Version Date 31-Aug-2016 | Protocol Date: | 31-Aug-2016 |

Another way to find out what will happen to you during this study is to read the chart below. Start reading at the left side and read across to the right, following the lines and arrows.



** Only the first 514 women who are enrolled on the study (in Group 1 or Group 2) will wear the accelerometer and complete the food and activity assessments and questionnaire.* The questionnaire will be filled out at your local treatment center and the accelerometer will be received in the mail from the BWEL Call Center at Dana-Farber Cancer Institute. Finally, you will take part in a telephone interview that will ask you questions about your physical activity and diet.

How long will I be in this study?

You will receive the health education program with or without the weight loss program for 2 years. After you finish the health education/weight loss programs, your doctor will continue to watch you for side effects and follow your condition for 8 years as part of your normal breast cancer follow up.

Since this is a weight loss study and involves exercise, you must be able to walk at least 2 blocks. If at any point during the study, you become injured or develop a medical condition that makes you unable to exercise or walk, you should let the study doctor know. You may continue to participate in the study as long as you get approval from your study doctor.

You should not plan to become pregnant within the first two years of the study when you are completing the health/weight loss programs. Check with the study doctor about what types of birth control, or pregnancy prevention, to use while in this study. If you become pregnant, it is important to let the study doctor know. You may still continue to participate in the study as long as you have approval from your OB/GYN and study doctor.

| | | | |
|--------------------------------------|--|---------------------------------|-------------|
| Principal Investigator: | Tara Sanft, MD | HIC #: | 1607018037 |
| Funding Source: | Alliance for Clinical Trials in Oncology | Sponsor Protocol Number: | A011401 |
| Sponsor ICF Template Version: | Protocol Version Date 31-Aug-2016 | Protocol Version: | Update #1 |
| Sponsor ICF Template Date: | Protocol Version Date 31-Aug-2016 | Protocol Date: | 31-Aug-2016 |

What extra tests and procedures will I have if I take part in this study?

Most of the exams, tests, and procedures you will have are part of the usual approach for your cancer. However, there are some extra measurements and tests that you will need to have if you take part in this study.

Before you begin the study:

You will need to have the following to find out if you can be in the study:

- Height and weight measurements

If these measurements show that you can take part in the study, and you choose to take part, then you will need the following extra tests and assessments. They are not part of the usual approach for your type of cancer.

You will need to have the following before you begin the weight loss/health education program:

- Height and weight measurements
- Measurement of the distance around your waist and hips
- Completion of a questionnaire that will ask about fatigue and quality of life, demographic information (race, education, income, etc.), smoking and alcohol use, health problems, medications you are taking, menstrual history, and about your thoughts on the questionnaire itself. It will take about 20 minutes to complete the survey. You may skip any question that makes you uncomfortable. However, you must provide information about your menstrual history and race/ethnicity in order to participate in the study.
- Collection of about 2-3 tablespoons of blood before you begin the weight loss/health education program. This sample is required in order for you to take part in this study because the research on the sample is an important part of the study. These blood samples will be collected at your local treatment center after you have not had anything to eat or drink for at least 12 hours. The blood samples will be used to test how the weight loss program affects a number of markers that have been linked to breast cancer, such as hormones involved in the way your body turns the food you eat into energy, markers of inflammation, and other blood markers linked to cancer. This research will allow investigators to learn which patients gain the most benefit from weight loss programs.

Blood collection is usually a very low risk procedure. There is a small risk of bleeding, bruising, infection, inflammation, blood clot or discomfort at the site of the blood collection. Attention will be taken to apply pressure following the procedure to reduce bleeding. You may feel dizzy or faint when blood is being withdrawn. We will ask you to lie down for a few minutes until any dizziness passes.

If any additional blood is left over after the tests are performed, then the remaining sample will be stored for future use in a “biobank.” Biobanking will be discussed in the “ADDITIONAL STUDIES” section. The remaining sample will only be saved for future use if you provide your consent by circling “yes” under question #2.

| | | | |
|--------------------------------------|--|---------------------------------|-------------|
| Principal Investigator: | Tara Sanft, MD | HIC #: | 1607018037 |
| Funding Source: | Alliance for Clinical Trials in Oncology | Sponsor Protocol Number: | A011401 |
| Sponsor ICF Template Version: | Protocol Version Date 31-Aug-2016 | Protocol Version: | Update #1 |
| Sponsor ICF Template Date: | Protocol Version Date 31-Aug-2016 | Protocol Date: | 31-Aug-2016 |

Your privacy is very important and the researchers will make every effort to protect it. Your test results will be identified by a unique code and the list that links the code to your name will be kept separate from your sample and health information.

Given that there is currently no information that would affect your clinical care that is being tested through these blood samples, these results will not be available to you or to your study doctor. However, at the completion of the trial, overall study findings will be shared with study participants and their doctors.

Neither you nor your health care plan/insurance carrier will be billed for the collection of the blood samples that will be used for this study.

- If you are one of the first 514 patients in this study, you will be asked to do the following before you can be assigned to one of the study groups and start the program(s):
 - Complete a questionnaire about your current quality of life, function and mood. You may skip any question that makes you uncomfortable. It will take you about 30-45 minutes to complete the questionnaire.
 - Wear an accelerometer (a special activity sensor), around your wrist for 24 hours a day, for 7 days.
 - Answer questions over the telephone about the physical activity that you did during the 7 days prior to the telephone call.
 - Answer questions over the telephone about the foods you had eaten over the 24 hours prior to the telephone call.

During the study (for 10 years after you are assigned to a study group):

- Weight measurements every 6 months for 3 years, then once per year
- Measurement of the distance around your waist and hips every 6 months for 3 years, then once per year
- Completion of a questionnaire about medications you are taking and other health problems you have developed every 6 months for 3 years, then once per year. It will take about 10 minutes to complete the questionnaire.
- Collection of about 2-3 tablespoons of blood at 6 and 24 months after you are assigned to a study group. This sample is required in order for you to take part in this study, just like the blood samples that were taken before you started the program(s). These blood samples will be collected at your local treatment center after you have not had anything to eat or drink for at least 12 hours.
- If you are one of the first 514 participants in this study, you will be asked to do the following at 6, 24 and 36 months after you are assigned to a study group:
 - Complete a questionnaire about your current quality of life, function and mood. You may skip any question that makes you uncomfortable. It will take you about 45 minutes to complete the questionnaire.
 - Wear an accelerometer (a special activity tracker), around your wrist for 24 hours a day, for 7 days.

| | | | |
|--------------------------------------|--|---------------------------------|-------------|
| Principal Investigator: | Tara Sanft, MD | HIC #: | 1607018037 |
| Funding Source: | Alliance for Clinical Trials in Oncology | Sponsor Protocol Number: | A011401 |
| Sponsor ICF Template Version: | Protocol Version Date 31-Aug-2016 | Protocol Version: | Update #1 |
| Sponsor ICF Template Date: | Protocol Version Date 31-Aug-2016 | Protocol Date: | 31-Aug-2016 |

- Answer questions over the telephone about the physical activity that you did during the 7 days prior to the telephone call.
- Answer questions over the telephone about the food you had eaten over the 24 hours prior to the telephone.

During this study you should not participate in another clinical trial that is testing a weight loss or physical activity program. You are welcome to take part in any type of program that you would like to that is not a part of a clinical trial, like dieting on your own or joining a gym or exercise class, regardless of whether you are assigned to Group 1 or Group 2.

What possible risks can I expect from taking part in this study?

If you choose to take part in this study, there is a risk that:

- You may lose time at work or home and spend more time in the hospital or doctor's office than usual
- You may be asked sensitive or private questions which you normally do not discuss
- Weight loss may be shown to not improve survival rates from breast cancer
- If you are assigned to the group that receives the weight loss program, 5-10% of the coaching phone calls will be recorded and reviewed by study staff to ensure that the program is being provided in the same way to all study participants. These recordings will be destroyed after the study is completed and will be kept in password protected files, but there is a small chance that someone could access them.
- Researchers from the University of Arizona Cancer Center will be working with the BWEL study team to conduct the telephone interviews that study diet and physical activity. If you are one of the first 514 study participants, your contact information may be shared with researchers from the University of Arizona Cancer Center so that they can contact you to conduct these interviews. This information will be kept in password-protected files and will be destroyed at the end of the study.
- All participants in this study receive a complimentary subscription to the *Harvard Women's Health Watch*, a magazine published by Harvard Medical School. Your mailing address will be shared with the magazine as part of the subscription process, but the magazine will not be given any of your health information.
- There is a risk someone could get access to the personal information in your medical records or other information researchers have kept about you. Someone might be able to trace this information back to you. The researchers believe the chance that someone will identify you is very small, but the risk may change in the future as people come up with new ways of tracing information. The researchers believe the chance these things will happen is very small, but cannot promise that they will not occur.

There is also a risk that you could have side effects from the weight loss intervention. These side effects are usually very mild. For example, you might experience sore muscles from exercising. You might also experience some gas or bloating as a resulting of making changes to your diet, like eating more fruits and vegetables.

| | | | |
|--------------------------------------|--|---------------------------------|-------------|
| Principal Investigator: | Tara Sanft, MD | HIC #: | 1607018037 |
| Funding Source: | Alliance for Clinical Trials in Oncology | Sponsor Protocol Number: | A011401 |
| Sponsor ICF Template Version: | Protocol Version Date 31-Aug-2016 | Protocol Version: | Update #1 |
| Sponsor ICF Template Date: | Protocol Version Date 31-Aug-2016 | Protocol Date: | 31-Aug-2016 |

Here are important points about side effects:

- The study doctors do not know who will or will not have side effects.
- Some side effects may go away soon, others could last a longer time

Here are important points about how you and the study doctor can make side effects less of a problem:

- Tell the study doctor if you notice or feel anything different so they can see if you are having a side effect.
- The study doctor may be able to treat some side effects.

Let your study doctor know of any questions you have about possible side effects. You can ask the study doctor questions about side effects at any time.

What possible benefits can I expect from taking part in this study?

It is not possible to know at this time if adding a weight loss program to the usual treatment for breast cancer will reduce the risk of your breast cancer coming back. However, losing weight has been shown in many studies to have other benefits, such as lowering the risk of diabetes, heart problems and other medical conditions. This study will also help researchers learn things that will help people in the future.

Can I stop taking part in this study?

Yes. You can decide to stop at any time. If you decide to stop for any reason, it is important to let the study doctor know as soon as possible. If you stop, you can decide whether or not to let the study doctor continue to provide your medical information to the organization running the study.

The study doctor will tell you about new information or changes in the study that may affect your health or your willingness to continue in the study.

The study doctor may take you out of the study:

- If your health changes and the study is no longer in your best interest
- If new information becomes available
- If you do not follow the study rules
- If the study is stopped by the sponsor, IRB or FDA.

What are my rights in this study?

Taking part in this study is your choice. No matter what decision you make, and even if your decision changes, there will be no penalty to you. You will not lose medical care or any legal rights.

For questions about your rights while in this study, call the Yale University Institutional Review Board at (203) 785-4688.

| | | | |
|--------------------------------------|--|---------------------------------|-------------|
| Principal Investigator: | Tara Sanft, MD | HIC #: | 1607018037 |
| Funding Source: | Alliance for Clinical Trials in Oncology | Sponsor Protocol Number: | A011401 |
| Sponsor ICF Template Version: | Protocol Version Date 31-Aug-2016 | Protocol Version: | Update #1 |
| Sponsor ICF Template Date: | Protocol Version Date 31-Aug-2016 | Protocol Date: | 31-Aug-2016 |

If after you have signed this form you have any questions about your privacy rights, please contact the Yale Privacy Officer at (203) 432-5919.

What are the costs of taking part in this study?

The weight loss and health education programs will be supplied at no charge while you take part in this study. It is possible that the programs may be discontinued before you finish them if the study is stopped early. Although not likely, if this occurs, your study doctor will talk to you about your options.

You and/or your health plan/insurance company will need to pay for all of the other costs of treating your cancer while in this study, including the cost of tests, procedures, or medicines to manage any side effects, unless you are told that certain tests are supplied at no charge. Before you decide to be in the study, you should check with your health plan or insurance company to find out exactly what they will pay for.

You will not be paid for taking part in this study.

What happens if I am injured or hurt because I took part in this study?

If you are injured or hurt as a result of taking part in this study and need medical treatment, please tell your study doctor. The study sponsors will not offer to pay for medical treatment for injury. Your insurance company may not be willing to pay for study-related injury. If you have no insurance, you would be responsible for any costs.

If you feel this injury was a result of medical error, you keep all your legal rights to receive payment for this even though you are in a study.

Confidentiality

Information about your study participation will be entered into your Electronic Medical Record (EMR). Once placed in your EMR, these results are accessible to all of your providers who participate in the EMR system. Information within your EMR may also be shared with others who are appropriate to have access to your EMR (e.g. health insurance company, disability provider.)

Who will see my medical information?

Your privacy is very important to us and the researchers will make every effort to protect it. For this study, your information, including your personal information and contact information, will be shared with the Alliance for Clinical Trials in Oncology, the group that is conducting this study. Your information will also be shared with the investigators and staff running the BWEL Call Center at the Dana-Farber Cancer Institute. In both of these places, your information will be kept stored in password-protected databases and/or in locked filing cabinets.

| | | | |
|--------------------------------------|--|---------------------------------|-------------|
| Principal Investigator: | Tara Sanft, MD | HIC #: | 1607018037 |
| Funding Source: | Alliance for Clinical Trials in Oncology | Sponsor Protocol Number: | A011401 |
| Sponsor ICF Template Version: | Protocol Version Date 31-Aug-2016 | Protocol Version: | Update #1 |
| Sponsor ICF Template Date: | Protocol Version Date 31-Aug-2016 | Protocol Date: | 31-Aug-2016 |

The protected health information that will be collected in this study includes demographics, medical history (including information about your cancer diagnosis and prior treatments you've received for your cancer), physical examinations and measurements, routine lab tests, review of adverse events and medications you take (past and present), vital signs, mammograms, MRI scans, CT scans, pregnancy tests, blood samples for research purposes, tissue samples for research purposes, information recorded in study questionnaires, diaries, and interviews, tracking data from an accelerometer or other activity tracker, survival follow-up information and records about any study drug(s) that you received.

Your information may be given out if required by law. For example, certain states require doctors to report to health boards if they find a disease like tuberculosis. However, the researchers will do their best to make sure that any information that is released will not identify you. Some of your health information, and/or information about your specimen, from this study will be kept in a central database for research. Your name or contact information will not be put in the database.

There are organizations that may inspect your records. These organizations are required to make sure your information is kept private, unless required by law to provide information. Some of these organizations are:

- The Alliance and other organizations from the National Clinical Trials Network that take part in this study
- The Dana-Farber Cancer Institute
- The Institutional Review Board, IRB, is a group of people who review the research with the goal of protecting the people who take part in the study.
- The Food and Drug Administration and the National Cancer Institute in the U.S., and similar ones if other countries are involved in the study.
- The U.S. Department of Health and Human Services (DHHS) agencies
- Representatives from Yale University and the Human Investigation Committee (the committee or Institutional Review Board that reviews, approves, and monitors research on human subjects), who are responsible for ensuring research compliance. These individuals are required to keep all information confidential
- Your providers who are participants in the Electronic Medical Record (EMR) system
- Those individuals at Yale who are responsible for the financial oversight of research including billings and payments
- The study doctor, Dr. Tara Sanft, and the Yale study team
- Drug regulatory agencies in other countries
- Governmental agencies to whom certain diseases (reportable diseases) must be reported
- Health care providers who provide services to you in connection with this study.
- Laboratories and other individuals and organizations that analyze your health information in connection with this study, according to the study plan.
- Data and Safety Monitoring Boards and others authorized to monitor the conduct of the Study

| | | | |
|--------------------------------------|--|---------------------------------|-------------|
| Principal Investigator: | Tara Sanft, MD | HIC #: | 1607018037 |
| Funding Source: | Alliance for Clinical Trials in Oncology | Sponsor Protocol Number: | A011401 |
| Sponsor ICF Template Version: | Protocol Version Date 31-Aug-2016 | Protocol Version: | Update #1 |
| Sponsor ICF Template Date: | Protocol Version Date 31-Aug-2016 | Protocol Date: | 31-Aug-2016 |

By signing this form, you authorize the use and/or disclosure of the information described above for this research study. The purpose for the uses and disclosures you are authorizing is to ensure that the information relating to this research is available to all parties who may need it for research purposes.

All health care providers subject to HIPAA (Health Insurance Portability and Accountability Act) are required to protect the privacy of your information. The research staff at the Yale School of Medicine and Yale-New Haven Hospital are required to comply with HIPAA and to ensure the confidentiality of your information. Some of the individuals or agencies listed above may not be subject to HIPAA and therefore may not be required to provide the same type of confidentiality protection. They could use or disclose your information in ways not mentioned in this form. However to better protect your health information, agreements are in place with these individuals and/or companies that require that they keep your information confidential.

This authorization to use and disclose your health information collected during your participation in this study will never expire.

Withdrawing Your Authorization to Use and Disclose Your Health Information

You may withdraw or take away your permission to use and disclose your health information at any time. You may withdraw your permission by telling the study staff or by writing to Dr. Tara Sanft at the Yale University, 300 George Street, Suite 120, New Haven, CT 06511.

If you withdraw your permission, you will not be able to stay in this study.

When you withdraw your permission, no new health information identifying you will be gathered after that date. Information that has already been gathered may still be used and given to others until the end of the research study, as necessary to insure the integrity of the study and/or study oversight.

Where can I get more information?

You may visit the NCI Web site at <http://cancer.gov/> for more information about studies or general information about cancer. You may also call the NCI Cancer Information Service to get the same information at: 1-800-4-CANCER (1-800-422-6237).

A description of this clinical trial will be available on <http://www.ClinicalTrials.gov>, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.

Who can answer my questions about this study?

You can talk to the study doctor about any questions or concerns you have about this study or to report side effects or injuries. Contact the study doctor, Dr. Tara Sanft, at (203) 785-2876.

| | | | |
|--------------------------------------|--|---------------------------------|-------------|
| Principal Investigator: | Tara Sanft, MD | HIC #: | 1607018037 |
| Funding Source: | Alliance for Clinical Trials in Oncology | Sponsor Protocol Number: | A011401 |
| Sponsor ICF Template Version: | Protocol Version Date 31-Aug-2016 | Protocol Version: | Update #1 |
| Sponsor ICF Template Date: | Protocol Version Date 31-Aug-2016 | Protocol Date: | 31-Aug-2016 |

If you would like to talk with someone other than the researchers to discuss problems, concerns, and questions you may have concerning this research, or to discuss your rights as a research subject, you may contact the Yale Human Investigation Committee at (203) 785-4688.

If after you have signed this form you have any questions about your privacy rights, please contact the Yale Privacy Officer at (203) 432-5919.

ADDITIONAL STUDIES SECTION:

This section is about optional studies you can choose to take part in

This part of the consent form is about optional studies that you can choose to take part in. You will not get health benefits from any of these studies. The researchers leading this optional study hope the results will help other people with cancer in the future.

The results will not be added to your medical records and you or your study doctor will not know the results.

You will not be billed for these optional studies. You can still take part in the main study even if you say “no” to any or all of these studies. If you sign up for but cannot complete any of the studies for any reason, you can still take part in the main study.

Circle your choice of “yes” or “no” for each of the following studies.

Optional Sample Collections for Additional Laboratory Studies and Biobanking for Possible Future Studies

Researchers are trying to learn more about cancer, diabetes, and other health problems. Much of this research is done using samples from your tissue, blood, urine, or other fluids. Through these studies, researchers hope to find new ways to prevent, detect, treat, or cure health problems.

Some of these studies may be about genes. Genes carry information about features that are found in you and in people who are related to you. Researchers are interested in the way that genes affect how your body responds to the weight loss/health education programs.

This study includes an optional substudy that will allow researchers to study the effect of the weight loss program on additional blood markers, and to look at how markers in breast tumor tissue relate to the effects of the weight loss program. If you choose to take part in this study, the study doctor for the main study would like to collect an additional blood sample and a sample of tissue that was removed during your previous breast biopsy or surgery for research on genes present in your tumor. A new biopsy or surgery will not be required.

In addition to requesting an extra blood sample and a sample of breast tumor tissue from a previous biopsy or surgery, the researchers conducting this study are requesting your permission to store left over blood in order to perform research in the future. If you choose to take part, and

| | | | |
|--------------------------------------|--|---------------------------------|-------------|
| Principal Investigator: | Tara Sanft, MD | HIC #: | 1607018037 |
| Funding Source: | Alliance for Clinical Trials in Oncology | Sponsor Protocol Number: | A011401 |
| Sponsor ICF Template Version: | Protocol Version Date 31-Aug-2016 | Protocol Version: | Update #1 |
| Sponsor ICF Template Date: | Protocol Version Date 31-Aug-2016 | Protocol Date: | 31-Aug-2016 |

there is extra tissue or blood available, then the researchers ask your permission to store and use your samples and related health information (for example, your response to cancer treatment, results of study tests and medicines you are given) for medical research. The research that may be done is unknown at this time. Storing samples for future studies is called “biobanking”. The Biobank is being run by the Alliance and supported by the National Cancer Institute.

You will be asked for permission to collect these extra samples and to store any extra samples. You can agree to one or both of these things. You will still be allowed to participate in the main study whether you agree to participate in these optional parts of the study or not.

WHAT IS INVOLVED?

If you agree to take part in the additional sample collection and/or the biobanking, here is what will happen next:

- 1) If you agree to provide additional blood samples and a sample from your breast tumor, about 2 teaspoons of blood will be collected from a vein in your arm and a sample from the tissue that was collected at the time of your surgery will be sent to the Biobank. Health-related information will also be sent to use in research. A new biopsy or surgery will not be required.
- 2) If you agree to have left over samples sent to the Biobank, all left over blood and tumor samples will be sent to the BioBank for future research.
- 3) Samples will be stored in the Biobank, along with samples from other people who take part. The samples will be kept until they are used up.
- 4) Qualified researchers can submit a request to use the materials stored in the Biobanks. A science committee at the clinical trials organization, and/or the National Cancer Institute, will review each request. There will also be an ethics review to ensure that the request is necessary and proper. Researchers will not be given your name or any other information that could directly identify you. Some related health information may be sent to the researcher.
- 5) Neither you nor your study doctor will be notified when research will be conducted or given reports or other information about any research that is done using your samples.
- 6) Some of your genetic and health information may be placed in central databases that may be public, along with information from many other people. Information that could directly identify you will not be included.

WHAT ARE THE POSSIBLE RISKS?

- 1) There is a risk that someone could get access to the personal information in your medical records or other information researchers have stored about you.
- 2) There is a risk that someone could trace the information in a central database back to you. Even without your name or other identifiers, your genetic information is unique to you. The researchers believe the chance that someone will identify you is very small, but the risk may change in the future as people come up with new ways of tracing information.
- 3) In some cases, this information could be used to make it harder for you to get or keep a job or insurance. There are laws against the misuse of genetic information, but they

| | | | |
|--------------------------------------|--|---------------------------------|-------------|
| Principal Investigator: | Tara Sanft, MD | HIC #: | 1607018037 |
| Funding Source: | Alliance for Clinical Trials in Oncology | Sponsor Protocol Number: | A011401 |
| Sponsor ICF Template Version: | Protocol Version Date 31-Aug-2016 | Protocol Version: | Update #1 |
| Sponsor ICF Template Date: | Protocol Version Date 31-Aug-2016 | Protocol Date: | 31-Aug-2016 |

may not give full protection. There can also be a risk in knowing genetic information. New health information about inherited traits that might affect you or your blood relatives could be found during a study. The researchers believe the chance these things will happen is very small, but cannot promise that they will not occur.

HOW WILL INFORMATION ABOUT ME BE KEPT PRIVATE?

Your privacy is very important to the researchers and they will make every effort to protect it. Here are just a few of the steps they will take:

- 1) When your sample(s) is sent to the researchers, no information identifying you (such as your name) will be sent. Samples will be identified by a unique code only.
- 2) The list that links the unique code to your name will be kept separate from your sample and health information. Any Biobank and the Alliance staff with access to the list must sign an agreement to keep your identity confidential.
- 3) Researchers to whom the Alliance sends your sample and information will not know who you are. They must also sign an agreement that they will not try to find out who you are.
- 4) Information that identifies you will not be given to anyone, unless required by law.
- 5) If research results are published, your name and other personal information will not be used.

WHAT ARE THE POSSIBLE BENEFITS?

You will not benefit from taking part. The researchers, using the samples from you and others, might make discoveries that could help people in the future.

ARE THERE ANY COSTS OR PAYMENTS?

There are no costs to you or your insurance. You will not be paid for taking part. If any of the research leads to new tests, drugs, or other commercial products, you will not share in any profits.

WHAT IF I CHANGE MY MIND?

If you decide you no longer want your samples to be used, you can call the study doctor, Dr. Tara Sanft, at (203) 785-2876 who will let the researchers know. Then, any sample that remains in the bank will no longer be used and related health information will no longer be collected. Samples or related information that have already been given to or used by researchers will not be returned.

WHAT IF I HAVE MORE QUESTIONS?

If you have questions about the use of your samples for research, contact the study doctor, Dr. Tara Sanft, at (203) 785-2876. If you would like to talk with someone other than the researchers to discuss problems, concerns, and questions you may have concerning this research, or to discuss your rights as a research subject, you may contact the Yale Human Investigation Committee at (203) 785-4688.

| | | | |
|--------------------------------------|--|---------------------------------|-------------|
| Principal Investigator: | Tara Sanft, MD | HIC #: | 1607018037 |
| Funding Source: | Alliance for Clinical Trials in Oncology | Sponsor Protocol Number: | A011401 |
| Sponsor ICF Template Version: | Protocol Version Date 31-Aug-2016 | Protocol Version: | Update #1 |
| Sponsor ICF Template Date: | Protocol Version Date 31-Aug-2016 | Protocol Date: | 31-Aug-2016 |

If after you have signed this form you have any questions about your privacy rights, please contact the Yale Privacy Officer at (203) 432-5919.

Please circle your answer to show whether or not you would like to take part in each option (include only applicable questions):

SAMPLES FOR THE LABORATORY STUDIES:

- 1) I agree to have an additional blood sample collected and to have a sample from my breast biopsy or surgery sent to the researchers from this study. I agree that my specimen sample(s) and related information may be used for the laboratory study(ies) described above.

YES NO

SAMPLES FOR FUTURE RESEARCH STUDIES:

- 2) My samples and related information may be kept in a Biobank for use in future health research.

YES NO

- 3) I agree that my study doctor, or their representative, may contact me or my physician to see if I wish to participate in other research in the future.

YES NO

This is the end of the section about optional studies.

| | | | |
|--------------------------------------|--|---------------------------------|-------------|
| Principal Investigator: | Tara Sanft, MD | HIC #: | 1607018037 |
| Funding Source: | Alliance for Clinical Trials in Oncology | Sponsor Protocol Number: | A011401 |
| Sponsor ICF Template Version: | Protocol Version Date 31-Aug-2016 | Protocol Version: | Update #1 |
| Sponsor ICF Template Date: | Protocol Version Date 31-Aug-2016 | Protocol Date: | 31-Aug-2016 |

My Signature Agreeing to Take Part in the Main Study

I have read this consent form or had it read to me. I have discussed it with the study doctor and my questions have been answered. I will be given a signed copy of this form. I agree to take part in the main study and any additional studies where I circled 'yes'.

Participant's signature _____

Date of signature _____

Signature of person(s) conducting the informed consent discussion _____

Date of signature _____

| | | |
|---|-----------|------|
| Person obtaining consent (print name) – only if applicable, otherwise blank | Signature | Date |
|---|-----------|------|

| | | |
|---|-----------|------|
| Interpreter/ Witness (print name) – only if applicable, otherwise blank | Signature | Date |
|---|-----------|------|